Genotype is associated with left ventricular reverse remodelling and early events in recent-onset dilated cardiomyopathy.

AIMS Recent-onset dilated cardiomyopathy (RODCM) is characterized by heterogeneous aetiology and diverse clinical outcomes, with scarce data on genotype-phenotype correlates. Our aim was to correlate individual RODCM genotypes with left ventricular reverse remodelling (LVRR) and clinical outcomes. METHODS AND RESULTS In this prospective study, a total of 386 Czech RODCM patients with symptom duration ≤6 months underwent genetic counselling and whole-exome sequencing (WES). The presence of pathogenic (class 5) or likely pathogenic (class 4) variants in a set of 72 cardiomyopathy-related genes was correlated with the occurrence of all-cause death, heart transplantation, or implantation of a ventricular assist device (primary outcome) and/or ventricular arrhythmia event (secondary outcome). LVRR was defined as an improvement of left ventricular ejection fraction to >50% or ≥10% absolute increase, with a left ventricular end-diastolic diameter ≤33 mm/m2 or ≥10% relative decrease. Median follow-up was 41 months. RODCM was familial in 98 (25%) individuals. Class 4-5 variants of interest (VOIs) were identified in 125 (32%) cases, with 69 (18%) having a single titin-truncating variant (TTNtv) and 56 (14%) having non-titin (non-TTN) VOIs. The presence of class 4-5 non-TTN VOIs, but not of TTNtv, heralded a lower probability of 12-month LVRR and proved to be an independent baseline predictor both of the primary and the secondary outcome. The negative result of genetic testing was a strong protective baseline variable against occurrence of life-threatening ventricular arrhythmias. Detection of class 4-5 VOIs in genes coding nuclear envelope proteins was another independent predictor of both study outcomes at baseline and also of life-threatening ventricular arrhythmias after 12 months. Class 4-5 VOIs of genes coding cytoskeleton were associated with an increased risk of life-threatening ventricular arrhythmias after baseline assessment. A positive family history of dilated cardiomyopathy alone only related to a lower probability of LVRR at 12 months and at the final follow-up. CONCLUSIONS RODCM patients harbouring class 4-5 non-TTN VOIs are at higher risk of progressive heart failure and life-threatening ventricular arrhythmias. Genotyping may improve their early risk stratification at baseline assessment.

[1]  B. Lewis,et al.  2023 ESC Guidelines for the management of cardiomyopathies. , 2023, European heart journal.

[2]  P. Lambiase,et al.  2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. , 2022, European heart journal.

[3]  E. Bollano,et al.  Prognostic differences in long‐standing vs. recent‐onset dilated cardiomyopathy , 2022, ESC heart failure.

[4]  A. Bayés‐Genís,et al.  Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. , 2021, Journal of the American College of Cardiology.

[5]  L. Mestroni,et al.  Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. , 2019, Journal of the American College of Cardiology.

[6]  Antonis Pantazis,et al.  Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators , 2019, JAMA network open.

[7]  D. Fatkin,et al.  Arrhythmic Genotypes in Familial Dilated Cardiomyopathy: Implications for Genetic Testing and Clinical Management. , 2019, Heart, lung & circulation.

[8]  P. Elliott,et al.  Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations. , 2018, Journal of the American College of Cardiology.

[9]  Kenneth L. Jones,et al.  Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell–Cell Adhesion Structures , 2018, JACC. Clinical electrophysiology.

[10]  Y. Pinto,et al.  Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy , 2017, European journal of heart failure.

[11]  L. Calò,et al.  Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. , 2016, Journal of the American College of Cardiology.

[12]  W. Stevenson,et al.  Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. , 2016, Journal of the American College of Cardiology.

[13]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[14]  S. Heymans,et al.  Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.

[15]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  Karen S. Frese,et al.  Atlas of the clinical genetics of human dilated cardiomyopathy. , 2014, European heart journal.

[17]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[18]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[19]  Y. Pinto,et al.  Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience , 2013, European journal of heart failure.

[20]  J. Kautzner,et al.  Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[21]  Marco Merlo,et al.  Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. , 2011, Journal of the American College of Cardiology.

[22]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[23]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.